Personalised prescribing for asthma - Is pharmacogenetics the answer?

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 3, 2003, Pages 279-289

  Dewar, Jane C ^b   Hall, Ian P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; DEXAMETHASONE; FENOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IPRATROPIUM BROMIDE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; MUSCARINIC RECEPTOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PRANLUKAST; PREDNISOLONE; SALBUTAMOL; SALMETEROL; STEROID; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HEREDITY; HUMAN; PHARMACOGENETICS; PREDICTION; PRESCRIPTION; REVIEW; SIDE EFFECT; SOCIAL ASPECT; TACHYPHYLAXIS; TREATMENT FAILURE;

ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG RESISTANCE; GREAT BRITAIN; HUMANS; PHARMACOGENETICS; PRESCRIPTIONS, DRUG;

EID: 0347925015     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021080     Document Type: Review

References (78)

1. Adcock, I. M., Lane, S. J., Brown, C. R., Lee, T. H., Barnes, P. J. (1995) Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J. Exp. Med. 182: 1951-1958
2. 4 gamma-glutamyl amino acid. Proc. Natl. Acad. Sci. 79: 1088-1091
3. Anon. (1997) The British Guidelines on Asthma Management. Thorax 52: S1
4. Asthma Audit 2001 Summary. Fact Sheet 18. National Asthma Campaign
5. 4 synthetase of rat basophil leukaemia cells: A novel particulate glutathione S-transferase. Arch. Biochem. Biophys. 230: 455-465
6. Ball, S. E., Scatina, J., Kao, J. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66: 288-294
7. Beato, M., Klug, J. (2000) Steroid hormone receptors: An update. Hum. Reprod. Update 6: 225-236
8. Beato, M., Herrlich, P., Schutz, G. (1995) Steroid hormone receptors: Many actors in search of a plot. Cell 83: 851-857
9. Bolger, G. B., Erdogan, S., Jones, R. E. (1997) Characterisation of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328: 539-548
10. Clark, J. D., Lin, L. L., Kriz, R. W. (1991) A novel arachidonic acid-selective cytosolic phospholipase A2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 65: 1043-1051
11. 4 synthase in bronchial biopsies from patients with aspirin-tolerant asthma. J. Clin. Invest. 101: 1-13
12. Daly, A. K., Fairbrother, K. S., Smart, J. (1998) Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol. Lett. 102-103: 143-147
13. 2 adrenoceptor polymorphism with total IgE in families with asthma. J. Allergy Clin. Immunol. 100: 261-265
14. Dewar, J. C., Wheatley, A. P., Venn, A., Morrison, J. F., Britton, J., Hall, J. P. (1998) Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin. Exp. Allergy 28: 442-448
15. Dixon, R. A., Diehl, R. E., Opas, E. (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282-284
16. Drazen, J. M. (1995) Leukotrienes in asthma and rhinitis. In: Busse, W., Holgate, S. T. (eds) Asthma and Rhinitis. Blackford Scientific Publications, Oxford, pp 838-850
17. 4 from the urine of patients with airway obstruction. Am. Rev. Respir. Dis. 146: 104-108
18. Drazen, J. M., Yandava, C. N., Dube, L. (1999) Pharmacogenetic association between ALOX-5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22: 185-190
19. Drazen, J. M., Silverman, E. K., Lee, T. H. (2000) Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56: 1054-1070
20. 2 adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97: 10483-10488
21. 3 receptor genes in normal and asthmatic subjects. Br. J. Pharmacol. 133: 43-48
22. Fritsche, E., Baek, S. J., King, L. M., Zeldin, D. C., Eling, T. E., Bell, D. A. (2001) Functional characterisation of cyclooxygenase-2 polymorphisms. J. Pharmacol. Exp. Ther. 299: 468-476
23. Funk, C. D., Hoshiko, S., Matsumo, T., Radmark, O., Samuelsson B. (1989) Characterisation of the human 5-lipoxygenase gene. Proc. Natl Acad. Sci. USA 86: 2587-2591
24. Green, S. A., Cole, G., Jacinto, M., Innis, M., Liggett, S. B. (1993) A polymorphism of the human beta2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268: 23116-23121
25. 2 adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33: 9414-9419
26. 2 adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345: 1213-1214
27. Hancox, R. J., Sears, M. R., Taylor, D. R. (1998) Polymorphism of the beta (2)-adrenoceptor and the response to long term beta (2) agonist therapy in asthma. Eur. Respir. J. 11: 589-593
28. Heise, C. E., O'Dowd, B. F., Figeuroa, D. J. (2000) Characterisation of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275: 30531-30536
29. 2 adrenoceptor polymorphism with reported childhood asthma. Br. Med. J. 316: 664
30. Huizenga, N. A., Koper, J. W., De Lange, P. (1998) A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83: 144-151
31. Hurley, D. M., Accili, D., Stratakis, C. A. (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J. Clin. Invest. 87: 680-686
32. Ieri, I., Tainaka, H., Morita, T. (2000) Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single strand conformational polymorphism analysis. Ther. Drug Monit. 22: 237-244
33. In, K. H., Asano, K., Beier, D., Grobholz, J. (1997) Naturally-occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99: 1130-1137
34. Ingelman-Sundberg, M., Oscarson, M., McLellan, R. A. (1999) Polymorphic human cytochrome P450 enzymes: An opportunity for individualised drug treatment. Trends Pharmacol. Sci. 20: 342-349
35. 2 adrenergic receptor on the response to regular albuterol in asthma. Am. J. Respir. Crit. Care Med. 162: 75-80
36. Ito, K., Lim, S., Caramori, G., Cosio, B., Chung, K. F., Adcock, I. M., Barnes P.J. (2002) A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA 99: 8921-8926
37. Jakobsson, P. J., Thoren, S., Morgenstern, R. (1999) Identification of human prostaglandin E synthase: A microsomal, glutathione dependent, inducible enzyme, constituting a potential novel drug treatment. Proc. Natl Acad. Sci. USA 96: 7220-7225
38. Jia, H., Hingorani, A. D., Sharma, P., Hopper, R., Dickerson, C., Trutwein, D., Lloyd, D. D., Brown, M. J. (1999) Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 34: 8-14
39. Johnsson, G., Astrom, A., Anderson, P. (1995) Budesonide is metabolised by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 50: 205-211
40. Kimura, M., Ieiri, I., Mamiya, K., Urae, A., Higuchi, S. (1998) Genetic polymorphism of cytochrome p450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20: 243-247
41. Koper, J. W., Stolk, R. P., De Lange, P., Huizenga, N. (1997) Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum. Genet. 99: 663-668
42. Lane, S. J., Lee T. H. (1991) Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid resistant bronchial asthma. Am. Rev. Respir. Dis. 143: 1020-1024
43. Lane, S. J., Arm, J. P., Staynov, D. Z., Lee, T. H. (1994) Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid resistant bronchial asthma. Hum. Genet. 11: 42-48
44. Lane, S. J., Atkinson, B. A., Swaminathan, R., Lee T. H. (1996) Hypothalamic-pituitary-adrenal axis in corticosteroid resistant bronchial asthma. Am. J. Crit. Care Med. 153: 557-560
45. Lane, S. J., Adcock, I. M., Richards, D., Hawrylowicz, C., Barnes, P. J., Lee, T. H. (1998) Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J. Clin. Invest. 102: 2156-2164
46. 4 by a dipeptidase released from the specific granules of human polymorphonuclear leucocytes. Immunology 48: 27-35
47. Liggett, S. B., Raymond, J. (1993) Pharmacology and molecular biology of adrenergic receptors. Catecholamines, Balliere's Clinical Endocrinology and Metabolism. 7 Edition, In: Bouloux, P. M. (ed.) Catecholamines, Balliere's Clinical Endocrinology and Metabolism. 7 Edition, Saunders, London, pp 279-306
48. 2 Agonists in Asthma Treatment. Marcel Dekker, New York, pp 19-34
49. 2 adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long acting beta2 agonist therapy. Clin. Sci. 96: 253-259
50. 2 adrenoceptor promoter polymorphisms: Extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 57: 61-66
51. Lynch, K. R., O'Neill, G. P., Liu, Q. (1999) Characterisation of the human cysteinyl leukotriene Cys LT1 receptor. Nature 399: 789-793
52. Malchoff, D. M., Brufsky, A., Reardon G (1993) A mutation of the glucocorticoid receptor in primary cortisol resistance. J. Clin. Invest. 91: 1981-1925
53. Manchee, G. R., Eddershaw, P. J., Ranshaw, L. E. (1996) The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsome is catalysed by CYP3A. Drug Metab. Dispos. 24: 555-559
54. Martinez, F. D., Graves, P. E., Baldini, M., Solomon, S., Erickson, R. (1997) Genetic polymorphisms of the beta2 adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100: 3184-3188
55. May, C. S., Caffin, J. A., Halliday, J. W., Bochner, F. (1980) Prednisolone pharmacokinetics in asthmatic patients. Br. J. Dis. Chest 74: 91-92
56. 2-adrenergic receptor regulate receptor expression. J. Clin. Invest. 102: 1927-1932
57. Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F.F., Kamataki, T. (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing in the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev. 3: 413-421
58. Palmer, L. J. (2001) Linkages and associations to intermediate phenotypes underlying asthma and allergic disease. Curr. Opin. Allergy Clin. Immunol. 1: 393-398
59. Piper, P. J. (1989) Leukotrienes and the airways. Eur. J. Anaesthesiol. 6: 241-255
60. 2 adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8: 334-339
61. Ruiz, M., Lind, U., Gavfels, M., Eggerston, G. (2001) Characterisation of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin. Endocrinol. 55: 363-371
62. Sachse, C., Brockmoller, J., Bauer, S., Roots, I. (1999) Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47: 445-449
63. 4 synthase in bronchial biopsies from aspirin intolerant asthmatic patients. Int. Arch. Allergy Immunol. 113: 355-357
64. Samuelsson, B. (1983) Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575
65. 4 synthase promoter polymorphism and risk of aspirin induced asthma. Lancet 350: 1599-1600
66. 4 synthase promoter. Am. J. Respir. Crit. Care Med. 159: A650
67. Schudt, C., Tenor, H., Hatzelman, A. (1995) PDE isoforms as targets for anti-asthma drugs. Eur. Respir. J. 8: 1179-1183
68. Scott, M. G., Swan, C., Wheatley, A. P., Hall, I. P. (1999) Identification of novel polymorphisms within the promoter region of the human beta-2-adrenergic receptor gene. Br. J. Pharmacol. 126: 841-844
69. Silverman, E., In, K. H., Yandava, C., Drazen, J. M. (1998) Pharmacogenetics of the 5-lipoxygenase pathway in asthma. Clin. Exp. Allergy 28: 164-170
70. Szefler, S. J., Leung, D.Y. (1997) Glucocorticoid resistant asthma: Pathogenesis and clinical implications for management Eur. Respir. J. 10: 1640-1647
71. Tan, S., Hall, I. P., Dewar, J., Dow, E., Lipworth, B. (1997) Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in asthmatics. Lancet 350: 995-999
72. Tattersfield, A. E., Knox, A. J., Britton, J. R., Hall, I.P. (2002) Asthma. Lancet 360: 1313-1322
73. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee (1998) Worldwide variation in the prevalence of symptoms of asthma, allergic rhino-conjunctivitis, atopic eczema: ISAAC. Lancet 351: 1225-1232
74. 2 adrenergic receptor in nocturnal and non-nocturnal asthma: Evidence that Gly 16 correlates with the nocturnal phenotype. J. Clin. Invest. 95: 1635-1641
75. Umino, Y., Hohjoh, H., Tokunaga, K. (2000) Novel single nucleotide polymorphisms (SNPs) at positions 497 (T/G)Q and 829 (T/C) in the human c-fos gene and haplotype association. Hum. Mutat. 16: 279
76. 4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106: 72-76
77. Wandel, C., Witte, J. S., Hall, J. M., Stein, C. M., Wood, A. J., Wilkinson, G. R. (2000) CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4 1B4 1B5′-promoter region polymorphism. Clin. Pharmacol. Ther. 68: 82-91
78. Zhang, Z. Y., Kaminsky, L. S. (1995) Characterisation of the human cytochromes p450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50: 205-211